Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ERCC1 | P07992 | 2/20 | 0.59 |
| ▸ | ERCC4 | Q92889 | 2/20 | 0.59 |
| ▸ | NR1H4 | Q96RI1 | 2/20 | 0.58 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.58 |
| ▸ | CARM1 | Q86X55 | 2/20 | 0.48 |
| ▸ | PRMT6 | Q96LA8 | 2/20 | 0.48 |
| ▸ | SMO | Q99835 | 1/20 | 0.47 |
| ▸ | PTGES | O14684 | 8/20 | 0.46 |
| ▸ | RXRA | P19793 | 1/20 | 0.43 |
| ▸ | F2 | P00734 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14368078 | 0.86 | ERCC1 (0.64) | ERCC1ERCC4CARM1PRMT6SMO | |
| SCHEMBL22060008 | 0.85 | NR1H4 (0.59) | ERCC1ERCC4NR1H4EPHX2CARM1 | |
| SCHEMBL22060011 | 0.84 | NR1H4 (0.59) | ERCC1ERCC4NR1H4PTGES | |
| SCHEMBL14573639 | 0.83 | ERCC1 (0.60) | ERCC1ERCC4CARM1PRMT6SMO | |
| SCHEMBL9931138 | 0.82 | PTGES (0.61) | ERCC1ERCC4NR1H4EPHX2SMO | |
| SCHEMBL14782824 | 0.81 | PTGES (0.59) | ERCC1ERCC4NR1H4PTGES | |
| SCHEMBL29463256 | 0.81 | PTGES (0.59) | ERCC1ERCC4NR1H4PTGES | |
| SCHEMBL13103587 | 0.79 | ERCC1 (0.54) | ERCC1ERCC4CARM1PRMT6SMO | |
| SCHEMBL14368077 | 0.79 | ERCC1 (0.59) | ERCC1ERCC4PTGES | |
| SCHEMBL12131750 | 0.78 | ERCC1 (0.70) | ERCC1ERCC4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200172473-A1 | DUAL MODULATORS OF FARNESOID X RECEPTOR AND SOLUBLE EPOXIDE HYDROLASE | JOHANN WOLFGANG GOETHE-UNIVERSITAET FRANKFURT AM MAIN (DE) | 2020-06-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200172473-A1 | DUAL MODULATORS OF FARNESOID X RECEPTOR AND SOLUBLE EPOXIDE HYDROLASE | NR1H4, NR1H3, NR1H2 | ERCC1 2685/4885ERCC4 1558/4885NR1H4 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.